On Thursday, Barclays (LON:BARC) maintained its Overweight rating and $140.00 stock price target for Merck (NYSE:MRK), in light of new data presented by competitor Arcus Biosciences (NYSE:RCUS) on its HIF-2α inhibitor, casdatifan. The data showcased a 34% objective response rate (ORR), with 25% confirmed ORR, which is seen as competitive to Merck's cancer drug, Welireg.
Barclays acknowledged the competitive nature of the data but noted that the differentiation in ORR was not as significant as anticipated, considering the dynamics of confirmed versus unconfirmed responses. Additionally, detailed progression-free survival (PFS) data is not expected until 2025, although early commentary suggests a median has not yet been reached, which is seen as positive.
The firm highlighted that Merck still has a substantial lead time, with expectations for combination data from its LITESPARK-011 trial in early 2026 and first-line data from LITESPARK-012 in late 2026. Even with the potential for Arcus to progress more quickly, Merck's timeline suggests a late-decade outcome for Arcus, solidifying Merck's advantage.
The analysis also pointed to the strong position of Merck's Keytruda, which could provide additional momentum for the company. The comparison of pivotal study details and timelines between Merck and Arcus underscores the head start that Merck currently holds in this space.
For further insights on the impact of Arcus's data, Barclays referred to the report "Arcus Biosciences, Inc.: Quick Takes - Encouraged by Arcus HIF2alpha Data - ORR In-Line to Above Historical Peer Data," published on October 24, 2024, which provides an analysis of the data presented by Arcus.
In other recent news, Merck has received European Commission approval for two new KEYTRUDA regimens to treat specific gynecologic cancers. This approval was based on the results of Phase 3 trials, demonstrating significant improvements in progression-free survival and overall survival for the patient groups.
In addition, Merck has recently acquired Modifi Biosciences, a company specializing in cancer therapy development, in a deal potentially worth up to $1.3 billion. This acquisition will aid in the development of novel cancer therapies known as KL-50.
Moreover, Merck announced positive results from the STRIDE-8 Phase 3 trial of its pneumococcal 21-valent conjugate vaccine, CAPVAXIVE. The vaccine showed a favorable safety profile and was found to be immunogenic across all 21 serotypes in adults with chronic conditions.
In a strategic collaboration with Exelixis (NASDAQ:EXEL), Merck is evaluating Exelixis' investigational drug zanzalintinib in combination with Merck's anti-PD-1 therapy KEYTRUDA. Truist Securities maintained a Buy rating on Exelixis, expressing confidence in zanzalintinib's potential and the collaboration's potential to increase revenue for Exelixis.
Finally, Truist Securities revised its price target for Merck from $143.00 to $132.00, following the acquisition of CN201 from Curon Biopharmaceutical and an increase in projected research and development expenses. These are the recent developments in Merck's operations.
InvestingPro Insights
Merck's strong market position, as highlighted in the article, is further supported by recent InvestingPro data. The company's market capitalization stands at an impressive $267.98 billion, reflecting its significant presence in the pharmaceutical industry. Merck's revenue for the last twelve months as of Q2 2024 reached $62.48 billion, with a solid revenue growth of 7.15% over the same period.
InvestingPro Tips reveal that Merck has maintained dividend payments for 54 consecutive years, demonstrating a commitment to shareholder returns that aligns with its long-term market strength. This consistency is particularly noteworthy given the competitive pressures discussed in the article. Moreover, Merck is expected to remain profitable this year, which is crucial as it continues to invest in its pipeline and defend its market position against emerging competitors like Arcus Biosciences.
For investors seeking a deeper understanding of Merck's financial health and market position, InvestingPro offers 11 additional tips, providing a comprehensive view of the company's prospects in the evolving pharmaceutical landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.